Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab

New research: Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab: Introduction Anti-disialoganglioside 2 (anti-GD2) monoclonal antibodies (mAbs) are associated with Grade ≥3 (≥G3)… #oncology https://